Literature DB >> 30706095

Comparison of hyperparathyroidism types and utility of dual radiopharmaceutical acquisition with Tc99m sestamibi and 123I for localization of rapid washout parathyroid adenomas.

Y S Kushchayeva1, S H Tella2, S V Kushchayev3, D Van Nostrand4, K Kulkarni5.   

Abstract

Tc99m-sestamibi dual-time imaging is a standard tool for localization of adenomas/hyperplasia in hyperparathyroidism. We investigated the degree and causes of localization failure among different types of hyperparathyroidism. Pre-operative parathyroid hormone levels and size of the gland were major determinants of Tc99m-sestamibi positivity; 123I scan may be helpful in localization failures.
INTRODUCTION: Tc99m-sestamibi dual-time imaging is a standard tool for localization of adenomas/hyperplasia in hyperparathyroidism. However, parathyroid adenomas/hyperplasia has been reported to washout as fast as normal thyroid tissue ("rapid washout") which may lead to diagnostic failure. We aimed to evaluate the determinants of rapid washout and to determine the role of subtraction imaging for detection of parathyroid adenomas/hyperplasia with rapid washout.
METHODS: Retrospective analysis of patients with hyperparathyroidism who have undergone Tc99m-sestamibi dual-time imaging and parathyroid surgery. Rapid washout was correlated to the type of hyperparathyroidism in surgically confirmed cases. Biochemical and pathological data were reviewed.
RESULTS: A total of 135 hyperparathyroidism patients met the inclusion criteria. Ninety-six (72%), 29 (21%), and 10 (7%) had primary, secondary, and tertiary hyperparathyroidisms, respectively. Rapid washout was identified in 28/87 glands (32%), 14/53 glands (26%), and 1/16 glands (6%) with primary, secondary, and tertiary hyperparathyroidisms, respectively. Glands that were positive on late-phase Tc99m-sestamibi scans were significantly large being 1.7 (IQR 1.4-2.3) vs. 1.45 (IQR 1-2) cm (p = 0.003). High parathyroid hormone levels (PTH) were associated with early-phase Tc99m-sestamibi positivity in both primary (p = 0.01) and secondary hyperparathyroidism (p = 0.03) but not with last phase (p = 0.11, p = 0.37, respectively). Correlative imaging with subtraction scintigraphy was positive in 14/16 (87.5%) parathyroid adenomas.
CONCLUSION: Pre-operative PTH levels and size of the gland were major determinants of Tc99m-sestamibi positivity on early-phase Tc99m-sestamibi scans, whereas size is an independent predictor of late-phase Tc99m-sestamibi positivity. Subtraction scintigraphy might be a useful tool in suspected cases of rapid washout adenomas/hyperplasia.

Entities:  

Keywords:  Hyperparathyroidism; PTH; Parathyroid adenomas; Rapid washout

Mesh:

Substances:

Year:  2019        PMID: 30706095     DOI: 10.1007/s00198-019-04846-6

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  34 in total

Review 1.  Biological factors influencing parathyroid localization.

Authors:  F Pons; J V Torregrosa; D Fuster
Journal:  Nucl Med Commun       Date:  2003-02       Impact factor: 1.690

2.  Preoperative dual-phase parathyroid imaging with tc-99m-sestamibi: accuracy and reproducibility of the pinhole collimator with and without oblique images.

Authors:  Anne K Arveschoug; Henrik Bertelsen; Birthe Vammen; Jens Brøchner-Mortensen
Journal:  Clin Nucl Med       Date:  2007-01       Impact factor: 7.794

3.  99mTc-MIBI scintigraphy of parathyroid adenomas and its relation to tumour size and oxyphil cell abundance.

Authors:  M Melloul; A Paz; R Koren; S Cytron; R Feinmesser; R Gal
Journal:  Eur J Nucl Med       Date:  2001-02

4.  Detection of ectopic parathyroid adenoma by early Tc-99m sestamibi imaging.

Authors:  Vani Vijayakumar; Matthew E Anderson
Journal:  Ann Nucl Med       Date:  2005-04       Impact factor: 2.668

5.  Relation between Tc-99m sestamibi uptake and biological factors in hyperparathyroidism.

Authors:  Tevfik Fikret Cermik; Fulya Oz Puyan; Atakan Sezer; Mehmet Fatih Firat; Sakir Berkarda
Journal:  Ann Nucl Med       Date:  2005-07       Impact factor: 2.668

6.  Tc-99m MIBI parathyroid scintigraphy and intact parathyroid hormone levels in hyperparathyroidism.

Authors:  Guang-Uei Hung; Shyh-Jen Wang; Wan-Yu Lin
Journal:  Clin Nucl Med       Date:  2003-03       Impact factor: 7.794

7.  Preoperative 123I/99mTc-sestamibi subtraction SPECT and SPECT/CT in primary hyperparathyroidism.

Authors:  Donald R Neumann; Nancy A Obuchowski; Frank P Difilippo
Journal:  J Nucl Med       Date:  2008-11-07       Impact factor: 10.057

8.  Early, postinjection MIBI-SPECT as the only preoperative localizing study for minimally invasive parathyroidectomy.

Authors:  Pinhas P Schachter; Nidal Issa; Mordechai Shimonov; Abraham Czerniak; Mordechai Lorberboym
Journal:  Arch Surg       Date:  2004-04

9.  Value of 123I-subtraction and single-photon emission computed tomography in addition to planar 99mTc-MIBI scintigraphy before parathyroid surgery.

Authors:  Francisca H Jorna; Pieter L Jager; Tjin H Que; Clara Lemstra; John T M Plukker
Journal:  Surg Today       Date:  2007-11-26       Impact factor: 2.549

10.  Incremental diagnostic value of preoperative 99mTc-MIBI SPECT in patients with a parathyroid adenoma.

Authors:  Mordechai Lorberboym; Irit Minski; Sorina Macadziob; Galina Nikolov; Pinhas Schachter
Journal:  J Nucl Med       Date:  2003-06       Impact factor: 10.057

View more
  2 in total

1.  Use of 99mTc-sestamibi SPECT/CT imaging in predicting the degree of pathological hyperplasia of the parathyroid gland: semi-quantitative analysis.

Authors:  Junhao Ma; Jun Yang; Chuanzhi Chen; Yimin Lu; Zhuochao Mao; Haohao Wang; Yan Yang; Zhongqi Li; Weibin Wang; Lisong Teng
Journal:  Quant Imaging Med Surg       Date:  2021-10

2.  Factors That Affect the Sensitivity of Imaging Modalities in Primary Hyperparathyroidism.

Authors:  Minting Zhu; Yang He; Tingting Liu; Bei Tao; Weiwei Zhan; Yifan Zhang; Jing Xie; Xi Chen; Hongyan Zhao; Lihao Sun; Jianmin Liu
Journal:  Int J Endocrinol       Date:  2021-02-20       Impact factor: 3.257

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.